NEW YORK, NY — January 9, 2026 — Leads & Copy — Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) has completed its public offering of 1,945,000 common shares at US$90.00 per share, resulting in gross proceeds of US$175,050,000.
The offering included the granting of a 30-day option for the underwriters to purchase up to 291,750 additional common shares at the public offering price, minus underwriting discounts and commissions. All securities in the offering were sold by Bright Minds.
The company plans to allocate the net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome. Funds will also support the initiation of phase 1 clinical drug trials for BMB-105, further research and development in earlier phase programs, and for general corporate and working capital needs.
Jefferies, TD Cowen, Piper Sandler & Co., and Cantor served as the joint book-running managers for the offering.
A shelf registration statement on Form F-3 was previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on September 2, 2025. The offering was conducted through a prospectus and prospectus supplement, which are part of the registration statement. Free copies of the final prospectus supplement and accompanying prospectus are accessible via EDGAR on the SEC website at www.sec.gov.
Copies can also be obtained from: (i) Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com, (ii) TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com, (iii) Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, or by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com, or (iv) Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.
This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities, nor will there be any sale of securities in any jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under local securities laws. All offers, solicitations, and sales of securities will be made in compliance with the Securities Act of 1933, as amended.
Bright Minds is a biotechnology company focused on creating treatments for neurological and psychiatric disorders. The company’s pipeline features compounds targeting key brain receptors to treat conditions with significant unmet needs such as epilepsy, depression, and other CNS disorders. The company says it is dedicated to providing therapies that can improve patients’ lives.
Bright Minds has a platform of selective serotonergic agonists that exhibit specificity at various serotonergic receptors, resulting in a portfolio of NCE programs within neurology and psychiatry.
Contact Information:
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.
Source: Bright Minds Biosciences Inc.
